UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 28, 2007
Biogen Idec Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other jurisdiction
of incorporation)
|
|
0-19311
(Commission
file number)
|
|
33-0112644
(IRS Employer
Identification No.) |
| |
|
|
14 Cambridge Center, Cambridge, Massachusetts
(Address of principal executive offices)
|
|
02142
(Zip Code) |
Registrant’s telephone number, including area code (617) 679-2000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 7.01 Regulation FD Disclosure.
On August 28, 2007, the registrant is presenting a Powerpoint slide showing a
TYSABRI® (natalizumab) safety update at the European Federation of Neurological
Societies (EFNS) Congress in Brussels, Belgium. The slide states that as of mid-July 2007 there
have been no new reports of confirmed cases of PML. The registrant had previously disclosed there
had been no new reports of confirmed cases of PML through May 23, 2007. A copy of the slide is
furnished as Exhibit 99.1 and is incorporated herein by reference.
The
most recent TYSABRI utilization update was provided on July 23,
2007 in a joint press release of the registrant and Elan Corporation on the one year anniversary of TYSABRI’s return to market in the U.S. and launch in the
European Union. Through mid-July 2007 there were approximately
14,000 patients on TYSABRI therapy worldwide (made up
of approximately 12,900 commercial patients and over 1,000 clinical trial patients).This
utilization information will not be updated during the EFNS presentation.
The
information included in this Item 7.01 and the Powerpoint slide
are being furnished pursuant to Item 7.01 of this Current Report on Form
8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor
be deemed incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Powerpoint slide showing a TYSABRI safety update